S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial

被引:0
作者
Jerome Sarris
Jenifer Murphy
Con Stough
David Mischoulon
Chad Bousman
Patricia MacDonald
Laura Adams
Sonia Nazareth
Georgina Oliver
Lachlan Cribb
Karen Savage
Ranjit Menon
Suneel Chamoli
Michael Berk
Chee H. Ng
Gerard J. Byrne
机构
[1] Western Sydney University,NICM Health Research Institute, Westmead
[2] Melbourne University,Professorial Unit, The Melbourne Clinic, Department of Psychiatry
[3] Swinburne University of Technology,Centre for Human Psychopharmacology
[4] Harvard Medical School,Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital
[5] University of Calgary,Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology
[6] The University of Melbourne,Department of Psychiatry
[7] The University of Queensland,Faculty of Medicine, Discipline of Psychiatry, Centre for Clinical Research, Royal Brisbane & Women’s Hospital, Herston
[8] Deakin University,IMPACT SRC, School of Medicine, Barwon Health
[9] The University of Melbourne,Florey Institute of Neuroscience and Mental Health
[10] The University of Melbourne,Orygen, The Centre of Excellence in Youth Mental Health
来源
Psychopharmacology | 2020年 / 237卷
关键词
Depression; S-Adenosylmethionine; Antidepressant; Clinical trial; Nutraceutical;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:209 / 218
页数:9
相关论文
共 105 条
[1]  
Arnold O(2005)Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry Eur Neuropsychopharmacol 15 533-543
[2]  
Saletu B(1961)Beck depression inventory (BDI) Arch Gen Psychiatry 4 561-571
[3]  
Anderer P(2017)Essential Oils and Their Constituents: An Alternative Source for Novel Antidepressants Molecules 22 1290-274
[4]  
Beck AT(2013)Massachusetts general hospital SAFER criteria for clinical trials and research Harv Rev Psychiatry 21 269-642
[5]  
Ward C(2003)The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM 96 635-1335
[6]  
Mendelson M(2008)The clinical relevance of changes in the Montgomery–Asberg depression rating scale using the minimum clinically important difference approach Curr Med Res Opin 24 1329-82
[7]  
de Sousa Damião(2017)Recent advances in predicting responses to antidepressant treatment F1000Research 6 619-45
[8]  
Silva Rayanne(1959)Hamilton anxiety rating scale (HAM-A) J Med 61 81-381
[9]  
Silva Epifanio(2002)Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database J Clin Psychopharmacol 22 40-376
[10]  
Gavioli Elaine(1986)SAFTEE: a technique for the systematic assessment of side effects in clinical trials Psychopharmacol Bull 22 343-389